SABS (SAB Biotherapeutics) Total Liabilities: $21.22 Mil (As of Mar. 2026)


SABS SAB Biotherapeutics Inc SABS
26 GF Score
Price $3.82
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics Total Liabilities?

SAB Biotherapeutics SABS +0.53% 26 Total Liabilities is $21.22 Mil as of Mar. 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

SAB Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $21.22 Mil.

SAB Biotherapeutics's quarterly Total Liabilities increased from Sep. 2025 ($18.37 Mil) to Dec. 2025 ($21.32 Mil) but then declined from Dec. 2025 ($21.32 Mil) to Mar. 2026 ($21.22 Mil).

SAB Biotherapeutics's annual Total Liabilities declined from Dec. 2023 ($26.64 Mil) to Dec. 2024 ($18.23 Mil) but then increased from Dec. 2024 ($18.23 Mil) to Dec. 2025 ($21.32 Mil).

SAB Biotherapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for SAB Biotherapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SAB Biotherapeutics Total Liabilities Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 42.59 19.85 26.64 18.23 21.32

SAB Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.71 18.11 18.37 21.32 21.22
SABS
26GF Score
SAB Biotherapeutics Inc SABS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SAB Biotherapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.681+(4.999+5.636
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=21.32

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=172.81-151.494
=21.32

SAB Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.852+(5.252+6.118
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=21.22

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=248.47-227.248
=21.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $21.22 Mil mean?
SAB Biotherapeutics (SABS) has a Total Liabilities of $21.22 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for SAB Biotherapeutics and its competitors.
Is SAB Biotherapeutics' Total Liabilities too high?
SAB Biotherapeutics' current Total Liabilities is $21.22 Mil. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' Total Liabilities compare to SRZN and GLSI?
SAB Biotherapeutics' Total Liabilities of $21.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current Total Liabilities is $21.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current Total Liabilities of $21.22 Mil. The current Total Liabilities is $21.22 Mil. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current Total Liabilities is $21.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score

Get the complete analysis for SABS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.82
Price